Healthcare and biopharma have always been critical sectors. Today, they have also become matters of national resilience and strategic security.
From supply-chain sovereignty to the ability to scale medical innovation, governments and industry leaders increasingly recognise that healthcare capacity is now a strategic priority.
Against this backdrop, Tanto Capital Partners is expanding its activities in the healthcare and pharmaceutical sectors.
Today, we are pleased to announce a strategic partnership between Tanto Capital Partners and Doalis Strategy.
Doalis Strategy works directly with boards, shareholders, and executive leadership at the inflection points where decisions are irreversible and outcomes directly shape enterprise value. Their focus on portfolio clarity, disciplined capital allocation, global structuring, and strategic transactions brings a rare quality of senior judgement to complex organisations — one that cuts through activity and restores focus on what truly matters.
Through this partnership, Tanto Capital will serve as Doalis’s dedicated financial partner across healthcare engagements, providing institutional-grade capital raising, M&A execution, and strategic finance capabilities to support companies navigating complex growth, transformation, and capital decisions.
It is a partnership built on a shared conviction: that fewer, better decisions — made with clarity, discipline, and alignment — create more enduring value than any volume of activity ever could.
Together, we will support ambitious healthcare and pharmaceutical companies at their most consequential moments — growth, restructuring, strategic transformation, and global expansion.
We are excited for what we will build together.